For the Inventor, By the Inventor

Enter assignee name

Hayward, CA, United States of America

Lynx Therapeutics, Inc.

USPTO Granted Patents = 56

CIPO Patents = 1

Forward Citations = 10,369

Loading Chart...

Loading Chart...

25 inventors (with patents filed for the assignee):

Sydney Brenner (28 out of 92 patents)

Sergei M Gryaznov (19 out of 84 patents)

Ronald G Schultz (10 out of 16 patents)

4. Stephen C Macevicz (8 out of 22 patents)

5. Glenn Albrecht (8 out of 12 patents)

6. Jer-Kang Chen (7 out of 13 patents)

7. Robert B Dubridge (6 out of 49 patents)

8. David H Lloyd (5 out of 7 patents)

9. Michael C Pallas (5 out of 28 patents)

10. George Stefan Golda (4 out of 29 patents)

11. John Bridgham (4 out of 13 patents)

12. Sarah N McCurdy (4 out of 4 patents)

13. Kevin P Corcoran (4 out of 11 patents)

14. Karen L Fearon (3 out of 26 patents)

15. Bernard L Hirschbein (3 out of 6 patents)

Core Competencies:

Oligonucleotide Tags

DNA Sequencing

Polynucleotide Sorting

Gene Expression Profiling

Electrophoresis

Adaptor-Based Sequence Analysis

Massively Parallel Sequencing

Solid Phase Synthesis

Diagnostic Applications

Polynucleotide Purification

Isothermal Amplification

Sulfurized Oligonucleotide Analogs

56 patents: Sort by Forward Citations

1. 6831994 - System and apparatus for sequential processing of analytes (2004-12-14),

2. 6806052 - Planar arrays of microparticle-bound polynucleotides (2004-10-19),

3. 6720179 - Method and compositions for ordering restriction fragments (2004-04-13),

4. 6654505 - System and apparatus for sequential processing of analytes (2003-11-25),

5. 6653077 - Method of screening for genetic polymorphism (2003-11-25),

6. 6518023 - Method of mapping restriction sites in polynucleotides (2003-02-11),

7. 6511802 - Solid phase selection of differentially expressed genes (2003-01-28),

8. 6406848 - Planar arrays of microparticle-bound polynucleotides (2002-06-18),

9. 6352828 - Oligonucleotide tags for sorting and identification (2002-03-05),

10. 6306597 - DNA sequencing by parallel oligonucleotide extensions (2001-10-23),

11. 6280935 - Method of detecting the presence or absence of a plurality of target sequences using oligonucleotide tags (2001-08-28),

12. 6265163 - Solid phase selection of differentially expressed genes (2001-07-24),

13. 6235475 - Oligonucleotide tags for sorting and identification (2001-05-22),

14. 6228589 - Measurement of gene expression profiles in toxicity determination (2001-05-08),

15. 6214191 - Electrophoresis apparatus and method (2001-04-10),

Company Overview

Lynx Therapeutics, Inc., based in Hayward, California, specializes in advanced oligonucleotide technologies that enhance genomic research and analysis. The company focuses on developing innovative solutions for DNA sequencing, gene expression profiling, and polynucleotide sorting. Their expertise includes adaptor-based sequence analysis and massively parallel sequencing, enabling researchers to gain deeper insights into genetic information. Lynx Therapeutics is committed to advancing the field of genomics through its cutting-edge technologies and methodologies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

56 Patents

#10 in Hayward, CA

#1,493 in California

#6,354 in US

#12,744 in the World

Hayward, CA, United States of America

Lynx Therapeutics, Inc.

Forward Citations = 10,369

25 inventors:

Sydney Brenner (28 out of 92 patents)

Sergei M Gryaznov (19 out of 84 patents)

Ronald G Schultz (10 out of 16 patents)

4. Stephen C Macevicz (8 out of 22 patents)

5. Glenn Albrecht (8 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Lynx Therapeutics, Inc.. Retrieved from https://idiyas.com/company/lynx-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…